Myeloma diagnosis can take over 5 months and require more than 4 medical consultations with more than 3 different specialists

Access, MPE, Myeloma, Patient evidenceLeave a comment

Brussels, 27 September 2022 – For some European myeloma patients, their diagnosis can take over 5 months, require more than 4 medical consultations and involve visits to at least 3 different medical specialists. These are some of the findings of pan-European research conducted by Myeloma Patients Europe (MPE) with the aim of exploring patient and doctor (haematologist) experiences of myeloma diagnosis. MPE ran a survey, and several focus groups and interviews, in which more than 600…

MPE launches survey on myeloma and AL amyloidosis diagnosis

AL amyloidosis, MPE, Myeloma, Patient evidenceLeave a comment

As part of MPE’s Year of Action, we are excited to announce the launch of the survey on myeloma and AL amyloidosis diagnosis. At MPE, we know that early diagnosis significantly improves the outcomes and quality of life of patients and their experience of healthcare. The survey seeks to understand the perspectives of myeloma and AL amyloidosis patients, as well as haematologists, on the diagnosis challenges. The survey will take approximately 5 minutes to complete and is…

MPE presents its poster on the impact of COVID-19 on the treatment and care of patients with myeloma and AL amyloidosis at IMW 2021

AL amyloidosis, Conferences, MPE, Patient evidenceLeave a comment

  As the SARS-CoV-2 (COVID-19) pandemic unfolded in 2020, Myeloma Patients Europe (MPE) became aware that the healthcare, treatment, and lives of myeloma and AL amyloidosis patients and their families were impacted by new health policies and national restrictions related to COVID-19.

Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMI

MPE, Patient evidenceLeave a comment

  An international multidisciplinary consortium, guided by the European Organisation for Research and Treatment of Cancer (EORTC), has been convened to generate recommendations to standardize the use, analysis, and interpretation of PRO data in cancer clinical trials. Myeloma Patients Europe (MPE) is one of the partners in this project representing the Workgroup or European Cancer Patient Advocacy Networks (WECAN).